Dianna Quan, MD
Neuromuscular Medicine · Aurora, CONPI 1881703262
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,495 of the $8,928 with a category attached, or 72.8%. AstraZeneca accounts for 64.7% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $5,789, 3.0 times the $1,919 reported in 2019.
Across 23 payments — averaging $388.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$6K
- Alnylam Pharmaceuticals Inc.$3K
- Pfizer$113
- Cadwell Industries, Inc$14
Across 136 payments — averaging $6561.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alnylam Pharmaceuticals Inc.$421K
- Janssen Research & Development, LLC$326K
- Amgen$56K
- Pfizer$42K
- Eidos Therapeutics, Inc.$33K
- Octapharma USA, Inc.$10K
- plus $3K from 1 others
What the payments were for
- Consulting fees$6,49573%
- Travel & lodging$1,54817%
- Food & beverage$88510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 4 | $5,776 |
| Alnylam Pharmaceuticals Inc. | 17 | $3,026 |
| Pfizer | 1 | $113 |
| Cadwell Industries, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few neuromuscular medicine providers in Coloradoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pyridostigmine Bromide | 13 | $1,393 |
| Azathioprine | 14 | $1,255 |
| Duloxetine Hcl | 33 | $1,006 |
| Nortriptyline Hcl | 25 | $881 |
| Diflunisal | 12 | $825 |
| Pregabalin | 16 | $478 |
| Gabapentin | 38 | $461 |
| Baclofen | 12 | $149 |
| Prednisone | 16 | $106 |
Paid to pharmacies, not to this prescriber.
Other neuromuscular medicine in Aurora
- Stacy DixonAurora$44K
- Monika Krzesniak SwinarskaAurora$1K
- Vera FridmanAurora$534
- Grace VeneziaAurora$138
- Maryam Tahmasbi SohiAurora$54
- Alexander DietzEnglewood$15K
- Katrina PackLafayette$3K
- Brian McIntyreDenver$166
- Jessica KelnerDenver$21
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.